534 research outputs found

    Don\u27t Give Me Diamonds, All I Want Is You

    Get PDF
    https://digitalcommons.library.umaine.edu/mmb-vp/1326/thumbnail.jp

    I\u27m trying so hard to forget you

    Get PDF
    https://digitalcommons.library.umaine.edu/mmb-vp/6029/thumbnail.jp

    One, Two, Three, Boys, : Over The Top We Go

    Get PDF
    https://digitalcommons.library.umaine.edu/mmb-vp/4283/thumbnail.jp

    I\u27m trying so hard to forget you

    Get PDF
    https://digitalcommons.library.umaine.edu/mmb-vp/1570/thumbnail.jp

    After \u27While

    Get PDF
    https://digitalcommons.library.umaine.edu/mmb-vp/1038/thumbnail.jp

    Fly Away Birdie To Heaven

    Get PDF
    https://digitalcommons.library.umaine.edu/mmb-vp/1437/thumbnail.jp

    Break the News to Mother

    Get PDF
    https://digitalcommons.library.umaine.edu/mmb-vp/1119/thumbnail.jp

    Belle of the Ball

    Get PDF
    https://digitalcommons.library.umaine.edu/mmb-vp/5144/thumbnail.jp

    Love O\u27Mine

    Get PDF
    https://digitalcommons.library.umaine.edu/mmb-vp/4477/thumbnail.jp

    The virtual heart as a platform for screening drug cardiotoxicity

    Get PDF
    To predict the safety of a drug at an early stage in its development is a major challenge as there is a lack of in vitro heart models that correlate data from preclinical toxicity screening assays with clinical results. A biophysically detailed computer model of the heart, the virtual heart, provides a powerful tool for simulating drug–ion channel interactions and cardiac functions during normal and disease conditions and, therefore, provides a powerful platform for drug cardiotoxicity screening. In this article, we first review recent progress in the development of theory on drug–ion channel interactions and mathematical modelling. Then we propose a family of biomarkers that can quantitatively characterize the actions of a drug on the electrical activity of the heart at multi‐physical scales including cellular and tissue levels. We also conducted some simulations to demonstrate the application of the virtual heart to assess the pro‐arrhythmic effects of cisapride and amiodarone. Using the model we investigated the mechanisms responsible for the differences between the two drugs on pro‐arrhythmogenesis, even though both prolong the QT interval of ECGs. Several challenges for further development of a virtual heart as a platform for screening drug cardiotoxicity are discussed
    corecore